Concerns over “behavioral issues” with Singulair developed over the past year. Merck periodically updated the drug’s labels to include warnings for tremors, depression and anxiety. FDA spokesperson Susan Cruzan said reports of suicides by “three or four” people who were taking Singulair prompted Merck to clarify suicide warnings on labels and patient information sheets in October 2007.
